JP6617155B6 - チロシンキナーゼ阻害剤およびそれを含む医薬組成物 - Google Patents

チロシンキナーゼ阻害剤およびそれを含む医薬組成物 Download PDF

Info

Publication number
JP6617155B6
JP6617155B6 JP2017553109A JP2017553109A JP6617155B6 JP 6617155 B6 JP6617155 B6 JP 6617155B6 JP 2017553109 A JP2017553109 A JP 2017553109A JP 2017553109 A JP2017553109 A JP 2017553109A JP 6617155 B6 JP6617155 B6 JP 6617155B6
Authority
JP
Japan
Prior art keywords
alkyl
compound
mmol
membered
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513150A (ja
JP2018513150A5 (enExample
JP6617155B2 (ja
Inventor
ロン，チャオフェン
チェン，チェンシア
チェン，シャオシン
チャン，ヤン
リウ，チュオウェイ
リ，ペン
チェン，シュンフイ
リャン，グイバイ
シェ，チェン
リ，チェンウェイ
フー，ジーフェイ
フー，グオピン
リ，ジアン
Original Assignee
グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド filed Critical グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド
Publication of JP2018513150A publication Critical patent/JP2018513150A/ja
Publication of JP2018513150A5 publication Critical patent/JP2018513150A5/ja
Priority to JP2019203698A priority Critical patent/JP6928774B2/ja
Application granted granted Critical
Publication of JP6617155B2 publication Critical patent/JP6617155B2/ja
Publication of JP6617155B6 publication Critical patent/JP6617155B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
JP2017553109A 2015-04-07 2016-04-07 チロシンキナーゼ阻害剤およびそれを含む医薬組成物 Active JP6617155B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019203698A JP6928774B2 (ja) 2015-04-07 2019-11-11 チロシンキナーゼ阻害剤およびそれを含む医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510161674 2015-04-07
CN201510161674.4 2015-04-07
PCT/CN2016/078703 WO2016161952A1 (zh) 2015-04-07 2016-04-07 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019203698A Division JP6928774B2 (ja) 2015-04-07 2019-11-11 チロシンキナーゼ阻害剤およびそれを含む医薬組成物

Publications (4)

Publication Number Publication Date
JP2018513150A JP2018513150A (ja) 2018-05-24
JP2018513150A5 JP2018513150A5 (enExample) 2018-08-02
JP6617155B2 JP6617155B2 (ja) 2019-12-11
JP6617155B6 true JP6617155B6 (ja) 2020-01-22

Family

ID=57072288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017553109A Active JP6617155B6 (ja) 2015-04-07 2016-04-07 チロシンキナーゼ阻害剤およびそれを含む医薬組成物
JP2019203698A Active JP6928774B2 (ja) 2015-04-07 2019-11-11 チロシンキナーゼ阻害剤およびそれを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019203698A Active JP6928774B2 (ja) 2015-04-07 2019-11-11 チロシンキナーゼ阻害剤およびそれを含む医薬組成物

Country Status (5)

Country Link
US (1) US10654808B2 (enExample)
EP (1) EP3293177B1 (enExample)
JP (2) JP6617155B6 (enExample)
CN (3) CN112028825B (enExample)
WO (1) WO2016161952A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009485C (en) * 2015-12-25 2020-08-25 Otsuka Pharmaceutical Factory, Inc. Phenylimidazole compound
JP6917448B2 (ja) * 2016-09-30 2021-08-11 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． チロシンキナーゼ阻害剤の結晶形、塩形態及び製造方法
US10800741B2 (en) 2017-02-07 2020-10-13 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Quinoline compound, preparation method and medical use therefor
CN107115344B (zh) * 2017-03-23 2019-06-14 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途
KR102327054B1 (ko) * 2017-08-29 2021-11-17 기초과학연구원 퀴놀린 유도체 및 alk와 변이된 alk의 저해제로서의 용도
KR20200047627A (ko) * 2017-08-31 2020-05-07 애브비 인코포레이티드 엑토뉴클레오티드 피로포스파타아제-포스포디에스테라아제 1(enpp-1) 저해제 및 그의 용도
WO2019062637A1 (zh) * 2017-09-28 2019-04-04 南京明德新药研发股份有限公司 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用
CN108623521B (zh) * 2018-03-22 2020-09-04 盐城师范学院 一种乐伐替尼的制备方法
CN110483482A (zh) 2018-05-15 2019-11-22 北京诺诚健华医药科技有限公司 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN110590839B (zh) * 2018-06-13 2022-04-05 四川海思科制药有限公司 一种乐伐替尼衍生物及制备方法和用途
CN110862397A (zh) * 2018-08-27 2020-03-06 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND THEIR USES
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES USED AS JANUS KINASE 2 INHIBITORS AND ASSOCIATED USES
CN109485620A (zh) * 2018-12-26 2019-03-19 安徽工大化工科技有限公司 一种2-甲氧基-6-甲氧基苯并噻唑的制备方法
EP3917536A4 (en) * 2019-02-01 2022-11-23 The Board of Trustees of the Leland Stanford Junior University ENPP1 INHIBITORS AND METHODS TO MODULATE THE IMMUNE RESPONSE
AU2020271855B2 (en) * 2019-04-12 2025-11-27 National Health Research Institutes Heterocyclic compounds as kinase inhibitors for therapeutic uses
CN111892536B (zh) * 2019-05-05 2022-06-28 北京福元医药股份有限公司 取代的喹啉甲酰胺类化合物及其用途
EP3985005A4 (en) 2019-06-14 2023-07-19 CGeneTech (Suzhou, China) Co., Ltd. FUSED RING COMPOUND AS DUAL FGFR AND VEGFR INHIBITOR
PE20221034A1 (es) * 2019-08-08 2022-06-17 B C I Pharma Derivados de quinolina como inhibidores de proteina quinasa
CN113321654B (zh) * 2020-02-28 2022-05-03 上海济煜医药科技有限公司 作为激酶抑制剂的稠合吡啶酮类化合物
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN113582924A (zh) * 2021-09-09 2021-11-02 四川国康药业有限公司 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
WO2023185638A1 (zh) * 2022-03-29 2023-10-05 广东众生睿创生物科技有限公司 一种喹啉衍生物的晶型及其制备方法
CN115215799B (zh) * 2022-08-12 2024-05-31 上海爱博医药科技有限公司 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0929526B1 (en) * 1996-09-25 2005-07-27 AstraZeneca AB Qinoline derivatives inhibiting the effect of growth factors such as vegf
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
MXPA03000252A (es) * 2000-08-09 2003-06-06 Astrazeneca Ab Derivados de quinolina que tienen actividad de inhibicion de fcev.
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
EP1660504B1 (en) * 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
AU2004309166B2 (en) 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
CN1993130B (zh) 2004-06-28 2010-06-23 布里斯托尔-迈尔斯斯奎布公司 用于制备稠合杂环激酶抑制剂的方法和中间体
WO2006125597A1 (en) * 2005-05-24 2006-11-30 Unilever N.V. Toothbrush
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
HUE035654T2 (en) * 2006-04-19 2018-05-28 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods for inhibiting CSF-1R signaling
US8304427B2 (en) * 2008-04-10 2012-11-06 Taiho Pharmaceutical Co., Ltd. Acylthiourea compound or salt thereof, and use thereof
CA2794086A1 (en) * 2010-03-24 2011-09-29 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
EP2586443B1 (en) * 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
AU2012223639B2 (en) * 2011-02-28 2015-03-19 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
CN102816175B (zh) * 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
DK2780338T3 (en) * 2011-11-14 2016-12-19 Ignyta Inc Uracil AS AXL- AND C-MET kinase inhibitors
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
AU2013364953A1 (en) * 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US10159666B2 (en) * 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations

Also Published As

Publication number Publication date
WO2016161952A1 (zh) 2016-10-13
CN106046007A (zh) 2016-10-26
US20190119217A1 (en) 2019-04-25
EP3293177B1 (en) 2024-11-27
CN112028825B (zh) 2025-03-14
EP3293177A1 (en) 2018-03-14
CN106046007B (zh) 2019-02-05
US10654808B2 (en) 2020-05-19
JP2018513150A (ja) 2018-05-24
JP6928774B2 (ja) 2021-09-01
JP2020037576A (ja) 2020-03-12
EP3293177A4 (en) 2018-12-12
JP6617155B2 (ja) 2019-12-11
CN107683279B (zh) 2020-11-03
CN112028825A (zh) 2020-12-04
CN107683279A (zh) 2018-02-09

Similar Documents

Publication Publication Date Title
JP6617155B6 (ja) チロシンキナーゼ阻害剤およびそれを含む医薬組成物
KR102089234B1 (ko) Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도
JP6774578B2 (ja) Ｍｅｋ阻害剤としてのクマリン環系化合物およびその応用。
JP2022506887A (ja) 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
CA3069829A1 (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
JP2020516606A (ja) Ａ２Ａ受容体阻害剤としての［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
JP2020505458A (ja) Ａｓｋ１阻害剤、その調製方法および使用
MX2014003800A (es) Derivado de pirazoloquinolina.
JP2018531218A (ja) Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
JP2018531218A6 (ja) Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
JP2024541910A (ja) プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法
KR20240089791A (ko) 메티오닌 아데노실트랜스퍼라제 2a (mat2a) 억제제 및 그의 용도
JP6836693B2 (ja) Ａ２ａ受容体アンタゴニストとしての縮合環誘導体
JP7328902B2 (ja) がん治療のためのイオンチャネル阻害剤化合物
JP2019528298A (ja) Ｐｄｅ４阻害剤
JP7050054B2 (ja) Ｐｄｅ４阻害剤としての縮合環系化合物
KR102547709B1 (ko) 아제티딘 유도체
CN114907385A (zh) 氮杂芳基化合物、其制备方法及应用
MX2011000329A (es) Derivados anticancerosos de 4-oxo-l, 4-dihidro-quinolina su preparacion y su uso terapeutico.
JP6900406B2 (ja) Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
CN106065012A (zh) 咪唑类化合物
JP2019524810A (ja) 抗ｈｃｍｖウイルス化合物
TW201736373A (zh) 作為免疫調節劑的三並環化合物
CN120230122A (zh) 具有jnk抑制活性的嘧啶类衍生物及其应用
HK40085073A (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171211

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181218

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191111

R150 Certificate of patent or registration of utility model

Ref document number: 6617155

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250